Codexis
6.03 %
-24.54 %
Yet to be announced
Company Overview
Codexis is a biotechnology company that develops and provides custom industrial enzymes and proteins through protein engineering technology. The company's main focus is on creating biocatalyst products that enable novel, cost-effective manufacturing processes for the production of pharmaceuticals, fine chemicals, and industrial enzymes.
The company partners with pharmaceutical companies to develop more efficient processes for manufacturing pharmaceutical intermediates and active pharmaceutical ingredients. Their technology platform, CodeEvolver, allows for the rapid development and optimization of proteins to meet specific industrial needs.
Revenue Sources
PassBased on review of Codexis' business activities and revenue sources, the company generates revenue primarily from enzyme engineering, pharmaceutical process development, and industrial biotechnology applications. None of these core business activities involve haram products or services like alcohol, tobacco, gambling, or interest-based financial services.
Reliance on Interest
| Reporting Date | Total Revenue | Total Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Dec. 31, 2024 | $21.46m | $28.8m | - | - | 0.00% | 0.00% |
| Sept. 30, 2024 | $12.83m | $29.39m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $7.98m | $30.71m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $17.07m | $28.96m | - | - | 0.00% | 0.00% |
According to the financial data provided, Codexis has reported zero interest income and zero interest expense across the last four quarters. The company appears to be operating without significant reliance on interest-bearing debt or interest-generating investments.
Operational Ethics
PassAfter reviewing available company documents, press releases, and operational locations, there is no evidence of current material associations with the state of Israel, Chinese Communist Party, or other entities involved in systematic human rights violations. The company's primary operations and R&D facilities are located in the United States.
Comments